Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N α2A-adrenoceptor transgenic mice

被引:61
作者
Zhu, QM [1 ]
Lesnick, JD [1 ]
Jasper, JR [1 ]
MacLennan, SJ [1 ]
Dillon, MP [1 ]
Eglen, RM [1 ]
Blue, DR [1 ]
机构
[1] Roche Biosci, Biol Res Ctr, Neurobiol Unit, Palo Alto, CA 94304 USA
关键词
rilmenidine; moxonidine; clonidine; alpha(2)-adrenoceptors; imidazoline receptors; RS-79948-197;
D O I
10.1038/sj.bjp.0702429
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We investigated the cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha(2A)-adrenoceptor mice. The-in vitro pharmacology of these agonists was determined at recombinant (human) alpha(2)-adrenoceptors and at endogenous (dog) alpha(2A)-adrenoceptors. 2 In wild-type mice, rilmenidine, moxonidine (100, 300 and 1000 mu g kg(-1), i.v.) and clonidine (30, 100 and 300 mu g kg(-1), i.v.) dose-dependently decreased blood pressure and heart rate. 3 In D79N alpha(2A)-adrenoceptor mice, responses to rilmenidine and moxonidine did not differ from vehicle control. Clonidine-induced hypotension was absent, but dose-dependent hypertension and bradycardia were observed. 4 In wild-type mice, responses to moxonidine (1 mg kg(-1), i.v.) were antagonized by the non-selective, non-imidazoline alpha(2)-adrenoceptor antagonist, RS-79948-197 (1 mg kg(-1), i.v.). 5 Affinity estimates (pK(i)) at human alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptors, respectively, were: rilmenidine (5.80, 5.76 and 5.33), moxonidine (5.37, <5 and <5)and clonidine (7.21, 7.16 and 6.87). In a [S-35]-GTP gamma S incorporation assay, moxonidine and clonidine were alpha(2A)-adrenoceptor agonists (pEC(50)/intrinsic activity relative to noradrenaline): moxonidine (5.74/0.85) and clonidine (7.57/0.32). 6 In dog saphenous vein, concentration-dependent contractions were observed (pEC(50)/intrinsic activity relative to noradrenaline): rilmenidine (5.83/0.70), moxonidine (6.48/0.98) and clonidine (7.22/0.83). Agonist-independent affinities were obtained with RS-79948-197. 7 Thus, expression of alpha(2A)-adrenoceptors is a prerequisite for the cardiovascular effects of moxonidine and rilmenidine in conscious mice, There was no evidence of I-1-imidazoline receptor-mediated effects. The ability of-these compounds to act as alpha(2A)-adrenoceptor agonists in vitro supports this conclusion.
引用
收藏
页码:1522 / 1530
页数:9
相关论文
共 40 条
[31]  
TIAN WN, 1994, MOL PHARMACOL, V45, P524
[32]  
TIBIRICA E, 1991, J PHARMACOL EXP THER, V256, P606
[33]   CHARACTERIZATION OF ALPHA-ADRENOCEPTORS PARTICIPATING IN THE CENTRAL HYPOTENSIVE AND SEDATIVE EFFECTS OF CLONIDINE USING YOHIMBINE, RAUWOLSCINE AND CORYNANTHINE [J].
TIMMERMANS, PBMWM ;
SCHOOP, AMC ;
KWA, HY ;
VANZWIETEN, HA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 70 (01) :7-15
[34]   INVOLVEMENT OF ALPHA(2)-ADRENOCEPTORS IN THE CARDIOVASCULAR EFFECTS OF MOXONIDINE [J].
URBAN, R ;
SZABO, B ;
STARKE, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 282 (1-3) :19-28
[35]  
URBAN R, 1994, J PHARMACOL EXP THER, V270, P572
[36]   OVERVIEW OF ALPHA-2-ADRENOCEPTOR AGONISTS WITH A CENTRAL ACTION [J].
VANZWIETEN, PA .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (09) :E3-E5
[37]   A comparative study of the reversal by different alpha(2)-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine [J].
VayssettesCourchay, C ;
Bouysset, F ;
Cordi, AA ;
Laubie, M ;
Verbeuren, TJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (03) :587-593
[38]  
WINTER JC, 1992, J PHARMACOL EXP THER, V263, P682
[39]   Imidazoline receptor agonist drugs: A new approach to the treatment of systemic hypertension [J].
Yu, A ;
Frishman, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (02) :98-111
[40]  
Zhu QM, 1997, BRIT J PHARMACOL, V122, pP70